Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab (COMPASS Trial)
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2 & 3
Waitlist Available
Sponsor: University of California, San Diego
No Placebo Group
Prior Safety Data
Breakthrough Therapy
Approved in 2 jurisdictions
Trial Summary
What is the purpose of this trial?To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: Ranibizumab 0.5 mgExperimental Treatment1 Intervention
Ranibizumab 0.5 mg Intravitreal Injection, monthly, open-label, for the duration of 1 year
Ranibizumab is already approved in European Union, United States for the following indications:
🇪🇺 Approved in European Union as Lucentis for:
- Neovascular age-related macular degeneration (nAMD)
- Diabetic macular edema (DME)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic retinopathy (DR)
- Myopic choroidal neovascularization (mCNV)
🇺🇸 Approved in United States as Lucentis/Susvimo for:
- Neovascular age-related macular degeneration (nAMD)
- Diabetic macular edema (DME)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic retinopathy (DR)
- Myopic choroidal neovascularization (mCNV)
Find a clinic near you
Research locations nearbySelect from list below to view details:
Shiley Eye Center, UCSDLa Jolla, CA
California Retina ConsultantsBakersfield, CA
California Retina ConsultantsSanta Barbara, CA
Medical Center Ophthalmology AssociatesSan Antonio, TX
Loading ...
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
Genentech, Inc.Industry Sponsor